1. Home
  2. RBCAA vs RAPP Comparison

RBCAA vs RAPP Comparison

Compare RBCAA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Bancorp Inc.

RBCAA

Republic Bancorp Inc.

HOLD

Current Price

$91.50

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$38.97

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBCAA
RAPP
Founded
1974
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
RBCAA
RAPP
Price
$91.50
$38.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
N/A
$48.50
AVG Volume (30 Days)
105.5K
374.3K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
2.41%
N/A
EPS Growth
N/A
24.34
EPS
0.77
N/A
Revenue
$417,495,000.00
N/A
Revenue This Year
$3.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$120.53
N/A
Revenue Growth
8.50
N/A
52 Week Low
$63.97
$13.43
52 Week High
$92.90
$43.76

Technical Indicators

Market Signals
Indicator
RBCAA
RAPP
Relative Strength Index (RSI) 72.88 52.97
Support Level $67.07 $33.54
Resistance Level N/A $40.61
Average True Range (ATR) 2.25 2.47
MACD 0.32 0.13
Stochastic Oscillator 83.03 42.09

Price Performance

Historical Comparison
RBCAA
RAPP

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: